How a Structured Products Attorney Reviews Structured Products

Financial institutions use structured products to transfer market risk to investors while generating fees for themselves. The issuer typically purchases a bond and simultaneously sells derivatives that give investors exposure to an underlying index or asset. If the underlying asset performs well, you may receive enhanced returns; if it performs poorly, your return may be capped, or you may lose part or all of your principal, depending on the product's design. From a practitioner's perspective, these products are often marketed to retail investors with promises of downside protection or enhanced income, yet that protection frequently comes with trade-offs that are buried in dense legal documentation. The prospectus discloses these terms, but many consumers do not fully grasp how the derivative component can eliminate upside gains or amplify losses.

Unlike mutual funds or exchange-traded funds (ETFs), which hold a diversified basket of securities and are regulated under different rules, structured products are typically issued by a single financial institution and are backed by that issuer's creditworthiness. Mutual funds and ETFs are required to disclose holdings and fees in standardized formats; structured products are governed by prospectus rules that, while legally binding, present information in formats that vary widely by product. Structured products often have no secondary market or a very limited one, meaning you may not be able to sell before maturity without accepting a significant discount. This illiquidity creates a material difference in risk profile compared to publicly traded funds.

The Securities Act of 1933 and the Securities Exchange Act of 1934 establish that structured products sold to consumers must be accompanied by a prospectus that contains detailed information about the product's mechanics, the underlying assets, the issuer's financial condition, and the risks involved. FINRA rules further require that any sales materials or communications about the product be fair, balanced, and not misleading. If an issuer or broker fails to disclose material facts or actively misrepresents the product, you may have grounds to pursue a claim for damages, though the burden of proof rests on you to demonstrate that the misrepresentation was material and that you relied on it. In practice, these disputes often turn on what a reasonable investor would have understood from the marketing materials and prospectus taken together, and courts may weigh competing interpretations of complex language differently depending on the record.

New York courts have held that brokers and financial advisors owe a duty to recommend products that are suitable for a customer's age, investment experience, financial situation, and risk tolerance. For structured products specifically, this means a broker cannot recommend a highly complex product with significant downside risk to a retiree seeking income without documenting why the product was appropriate for that customer. If a broker recommends an unsuitable product and you suffer losses, you may bring a claim in New York state court or through arbitration under FINRA rules. Burden of proof and remedies vary depending on whether you bring a claim based on breach of contract, negligence, or violation of securities statutes, and New York courts have shown willingness to examine whether disclosure was sufficient when the product's actual mechanics differed materially from how the broker described them to the customer.

When a structured product issuer files for bankruptcy, the security you hold becomes a general unsecured debt owed by the issuer. Secured creditors, employees owed wages, and administrative expenses are paid first, and only then do unsecured creditors like you receive distributions from remaining assets. In many cases, unsecured creditors recover pennies on the dollar or nothing at all. This risk is particularly acute if you purchase a structured product issued by a smaller or less well-capitalized financial institution, or if you purchase shortly before the issuer faces financial stress. The prospectus typically includes a credit rating for the issuer, but rating agencies have been criticized for not always updating ratings quickly when an issuer's condition deteriorates.

From a practitioner's perspective, consumers who purchase structured products should preserve all marketing materials, prospectuses, confirmation statements, and correspondence with the broker or advisor. If you have concerns about how a product was presented to you, document those concerns in writing to the broker and your advisor immediately, and request written confirmation of the product's suitability for your profile. Before any material event such as a market downturn, issuer rating change, or product maturity, formalize your understanding of the product's mechanics and your original investment objectives in a contemporaneous memo or email to your advisor, as courts and arbitrators often weigh what the record shows you knew and when you knew it. This documentation can be decisive if a dispute arises later about whether the product was suitable or whether risks were adequately disclosed.

Consider the product's payoff structure by asking whether your upside is capped, your downside is protected, or both, and whether the protection or enhancement is worth the fee you are paying. Review the issuer's credit rating and financial statements to understand the risk that the issuer will default. Assess liquidity by asking whether you can sell the product on a secondary market before maturity, what bid-ask spreads typically are, and whether the product is actively traded or thinly traded. Compare the product to simpler alternatives such as index funds or bonds that offer similar exposure without the embedded derivatives and issuer credit risk. If a broker cannot clearly explain why the structured product is better for you than a simpler alternative, that is often a signal that the product may not be suitable. For guidance on how structured products fit within a broader investment strategy, you may also consult resources on structured financial products and structured investment products available through financial law specialists.

The SEC oversees broker conduct and product disclosures, and FINRA enforces rules against unsuitable recommendations and sales practice violations. If you have a concern about how a structured product was sold to you, you can file a complaint with FINRA's dispute resolution program, submit a complaint to the SEC through its website, or contact your state securities regulator. Documenting your complaint contemporaneously, including the dates you raised concerns with your broker and the broker's response, strengthens your position if you later pursue a formal claim. Many consumers delay filing complaints because they hope market conditions will improve or they do not understand their options, but delay can affect your legal rights and the evidence available to support your claim.